Bacteria-Contaminated Hand Soaps and Cleansers Recalled

A company based in New Jersey specializing in health and skincare products is taking proactive steps to recall several cleansers and hand soaps. This action is prompted by the discovery of bacterial contamination in these items.

DermaRite Industries, LLC, is recalling certain batches of its DermaKleen antiseptic lotion soap that comes with vitamin E, available in both 1,000-milliliter and 800-milliliter packages. The recall also extends to KleenFoam's antibacterial foam soap with aloe vera, which is distributed in 1,000-milliliter containers. Additionally, the recall affects DermaSarra's external analgesic and PeriGiene's antiseptic cleanser, both in 7.5-ounce bottles. These products have been circulated in the United States and Puerto Rico.

The expiration dates of the affected products fall between July 2025 and February 2027. A comprehensive list detailing affected lot and reorder numbers is available for those seeking more information.

This recall notification was officially issued on August 8 and further publicized on the company's website over the weekend.

In its public statement, DermaRite has confirmed the presence of Burkholderia cepacia, a bacterium known to cause severe or potentially fatal infections in the recalled products.

DermaRite warns that the tainted items may pose risks, especially for those with weakened immune systems. The use of these products by or for such individuals could lead to localized infections. In more severe cases, there is a risk of the bacteria entering the bloodstream, resulting in critical sepsis.

Burkholderia cepacia is a bacterium found in natural environments like soil and water, easily transferring between contaminated surfaces and individuals.

Infected individuals might not showcase immediate symptoms, yet possible signs include respiratory difficulties, fever, or fatigue.

People with compromised immune systems or existing lung diseases, such as cystic fibrosis, are particularly vulnerable to B. cepacia. Additionally, this bacterium often displays resistance to many antibiotics, complicating treatment options.

To address the issue, DermaRite has communicated with its customers and distributors, urging them to inspect their stocks and dispose of any affected products following their facility protocols.

As of now, DermaRite hasn't received any adverse reaction reports related to the recalled items. Consumers experiencing any symptoms post-product use are advised to contact their healthcare providers and report such cases through the FDA's MedWatch Adverse Event Reporting program.

For additional information or queries concerning the recall, customers can reach DermaRite at (973) 569-9000, extension 104, Monday through Friday, 9 a.m. to 5 p.m. EST, or via email at voluntary.action@dermarite.com.